Bahsani: Yemen’s Presidential Council will Seek to Achieve Stability in North, South

 Major General Faraj Salmin al-Bahsani, member of the Yemeni Presidential Leadership Council
Major General Faraj Salmin al-Bahsani, member of the Yemeni Presidential Leadership Council
TT

Bahsani: Yemen’s Presidential Council will Seek to Achieve Stability in North, South

 Major General Faraj Salmin al-Bahsani, member of the Yemeni Presidential Leadership Council
Major General Faraj Salmin al-Bahsani, member of the Yemeni Presidential Leadership Council

Major General Faraj Salmin al-Bahsani, member of the Yemeni Presidential Leadership Council, confirmed that the council will lead the stage in the North and the South towards stability, calling for placing the national project above any other considerations.

In an interview with Asharq Al-Awsat, Bahsani noted that a draft roadmap was currently being discussed and included a first phase of six months to stabilize the ceasefire, then a preparation stage of three months, followed by a transitional phase that extends over two years to discuss the form of the state.

He also stressed that Saudi Arabia was leading the process of rapprochement between the Yemeni legitimacy and the Houthi group, based on good neighborliness and brotherhood between the two countries, expressing his confidence that the Kingdom would continue to stand by the Presidential Leadership Council and the legitimate government.

Bahsani said, however, that the proposed draft peace map “collided at the beginning with the intransigence of the Houthi militia, which practices the Iranian method of procrastination.”

“These militias do not care about ending the war or the suffering of the people through regional and international opportunities to bring peace to Yemen. All they want from the war and the coup against the state is to control the institutions and seize power,” he underlined.

According to Bahsani, the most important axes of “the draft peace map include a first phase of six months, in which the ceasefire is established and other measures are taken without the militia’s intervention.”

Those measures seek to facilitate commercial activity and the citizens’ movement in areas controlled by the Houthis.

“As for the second phase, it will last for three months, during which the plans and programs for the transitional phase will be prepared,” he underlined.

The member of the Yemeni Presidential Leadership Council stated that Saudi Arabia was leading the process of rapprochement between the legitimacy and the Houthis, pointing out that neither the council nor the legitimate government participated in any direct dialogues with the Houthi militia.

He also stressed that the Saudi-Iranian agreement signed on March 10 will reflect positively on major regional files, including Yemen.

“Saudi Arabia puts all its diplomatic weight to solve this file with the Republic of Iran and to stop Tehran’s backing of the Houthi militia,” Bahsani told Asharq Al-Awsat, adding that the Houthis used this support “to kill the Yemeni people and tamper with the stability of the region as a whole, not just Yemen.”

The member of the Presidential Leadership Council emphasized that the war was not over yet, and that the Yemeni army was ready for the worst possibilities if the Houthis insisted on a new round of fighting.

With regards to the peace efforts led by Saudi Arabia, the UN envoy and a number of “brotherly and friendly” countries that took place during the past years, the Houthi group has constantly renounced these agreements, Bahsani said.

“This is what made the legitimacy demand guarantees for the implementation of any future agreements,” he added.

The Yemeni official expressed his doubts over the commitment of the Houthi group to the peace map. On the other hand, he noted that the structure of the state and the fate of the Yemenis will be decided in the North and the South during the upcoming arrangements.

“Thus, it will be a great responsibility for the brothers in the North to get rid of these militias and their weapons, and as southerners, we will be supportive of any role in this regard,” he remarked.

According to Bahsani, the Presidencial Council was able to complete many achievements since its formation, mainly restructuring and reactivating the judiciary, reviving efforts to advance the peace process and consolidate stability in the liberated governorates, and addressing many issues within the military.



Hevolution CEO Discusses Career in Innovation, Medicine, and Business

Dr. Mehmood Khan, CEO of the Hevolution Foundation
Dr. Mehmood Khan, CEO of the Hevolution Foundation
TT

Hevolution CEO Discusses Career in Innovation, Medicine, and Business

Dr. Mehmood Khan, CEO of the Hevolution Foundation
Dr. Mehmood Khan, CEO of the Hevolution Foundation

Dr. Mehmood Khan, CEO of the Hevolution Foundation, the largest philanthropy organization funding aging medicine in the world, expressed that receiving Saudi citizenship will boost his scientific and practical capabilities.
He said this new status will help him advance his research, especially in addressing aging.
This comes as part of a recent royal decree granting Saudi citizenship to several notable scholars, doctors, researchers, and innovators.
“Our Chairman, his Royal Highness (Crown Prince Mohammed bin Salman), has very high expectations of our work and the impact we need to do; We were created in part because of his vision,” Khan told Asharq Al-Awsat.
“Living up to the expectations and challenges we get faced with is itself exciting, but it is challenging,” revealed Khan, affirming that Hevolution’s team is “up to that task.”
Khan, who has experience in both corporate and medical fields, told Asharq Al-Awsat that his work across academic, public, and private sectors has been a continuous learning process, with each area enhancing the others.
According to the CEO, these industries are interconnected, and combining their strengths often leads to the best solutions.
This insight inspired the Hevolution initiative, which brings together the scientific community, NGOs, pharmaceutical companies, policymakers, academia, biotech firms, CEOs, and others to promote healthy aging.
Khan highlighted the value of integrating insights from different sectors.
Academia provides detailed research, the public sector offers insights on population health and regulations, and the corporate world brings innovation and efficiency, explained Khan, adding that by merging these perspectives, the world can tackle complex health challenges more effectively.
“We’ve been working through, and are now investing, funding and partnering with over 200 scientists around the world, and over 150 different university labs,” said Khan.
Hevolution uses this integrated approach to advance healthy aging.
This initiative embodies my passion for addressing major challenges and offers a significant opportunity to make a global impact.
Khan talked about the first $400 million commitment Hevolution made in the last 23 months, calling it “unprecedented.”
“There has never been a non-profit organization in the world that has gone from not existing to now becoming the largest philanthropy funding aging biology and medicine in the world,” affirmed Khan.
Khan stressed that work at Hevolution not only pushes scientific boundaries but also promotes cross-sector collaboration to improve global health outcomes.
Since Khan’s early days in medical school, he’s been deeply interested in nutrition and population health, which was an unconventional focus back then. This journey set the foundation for his later work in community health.
Khan’s time as an endocrinology faculty member at the Mayo Clinic was crucial. He led programs on diabetes, endocrine diseases, metabolism, and nutrition, which strengthened his expertise in designing disease prevention systems.
In the private sector, Khan took on a key role at Takeda Pharmaceutical as the global head of R&D, which shaped his approach to innovative healthcare solutions.
At PepsiCo, as Chief Scientific Officer, he learned crucial principles of scale, impact, transformation, and tackling global challenges.
As CEO of Hevolution, Khan uses all his professional experience to advance the foundation’s mission of developing health sciences to address age-related diseases.
Khan serves on the boards of Reckitt Benckiser and the Saudi Research, Development, and Innovation Authority (RDIA).
He is the CEO of Life Biosciences, a member of Saudi Arabia’s biotechnology strategy committee, and the chair of the advanced technology visiting committee at the US National Institute of Standards and Technology (NIST).
Khan told Asharq Al-Awsat that he feels honored to have recently become a Saudi citizen by royal decree, while also holding dual US and UK citizenship. This helps him lead Hevolution effectively and work closely with international partners.
Khan commented on his recent Saudi citizenship, saying that in addition to feeling honored to receive Saudi citizenship by royal decree, alongside other distinguished individuals, this recognition is a great privilege.
Being a Saudi citizen, as per Khan, is a significant milestone and acknowledges the progress in his work in aging science and global health. It also strengthens Khan’s commitment to the work at Hevolution.
Khan noted that this new status enhances his ability to build relationships and collaborate within the Kingdom and internationally. It offers a deeper connection with the local community and better opportunities to engage with policymakers and leaders.
He also said that this recognition boosts Hevolution’s global presence and credibility, making the foundation’s collaborations with international scientists and business leaders stronger. It positions Hevolution as a key player in addressing age-related diseases.
Khan emphasized that this honor reflects the hard work and innovation of Hevolution’s entire team.
The CEO said that it was collective efforts that have made this achievement possible.
Khan also said he is excited to engage more deeply with the scientific and medical community in the Kingdom, adding that his new citizenship helps him contribute to Vision 2030 and the national biotechnology strategy, promoting innovation and attracting top global talent.